News
A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...
One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...
Pharmalittle: We’re reading about a Merck shot for RSV, a lawsuit over an Arkansas PBM law, and more
Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...
Clesrovimab has been held up by MSD (known as Merck & Co in the US and Canada) as offering simpler dosing and better clinical ...
Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...
Explore more
Results that may be inaccessible to you are currently showing.
Hide inaccessible results